Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Osivelotor · GBT-021601, GBT-601

Small molecule · Modulator of Hemoglobin subunit beta (hemoglobin S) (HBB) · developed by Pfizer

Phase 1 Most advanced trial
PFE Developer

What is Osivelotor?

Osivelotor is an orally bioavailable agent that covalently binds sickle cell hemoglobin S (HbS). It stabilizes hemoglobin in its oxygenated state, which increases oxygen affinity and inhibits HbS polymerization and red blood cell sickling. It is being studied in sickle cell disease.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
GBT-021601, GBT-601, PF-07940367
Drug type
Small molecule
Targets
Hemoglobin subunit beta (hemoglobin S) (HBB)
Mechanism
Modulator of Hemoglobin subunit beta (hemoglobin S) (HBB)
Pathways
HbS polymerization, red blood cell sickling, oxygen affinity of hemoglobin
Therapy area
Hematology
Developer
Pfizer (PFE)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 1
UNII
UK749B4S16

Conditions studied

Healthy

More from Pfizer

Sources

Updated Oct 25, 2026. Something wrong or missing? Report it on the PFE page.

Follow PFE, the company behind Osivelotor

See PFE's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

PFE catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.